Dr Timothy Hughes

2025

• Byrne, R. A. et al. 2025. The schizophrenia-associated gene CSMD1 encodes a complement classical pathway inhibitor predominantly expressed by astrocytes and at synapses in mice and humans. Brain, Behavior, and Immunity 127 , pp.287-302. (10.1016/j.bbi.2025.03.026)
• Kamiya, T. et al., 2025. Absence of complement terminal pathway activity in C6-deficient mice prolongs survival in a mouse model of severe malarial infection. Immunobiology 230 (6) 153140. (10.1016/j.imbio.2025.153140)

2024

• Nguyen, V. D. , Hughes, T. R. and Zhou, Y. 2024. From complement to complosome in non‐alcoholic fatty liver disease: when location matters. Liver International 44 (2), pp.316-329. (10.1111/liv.15796)

2023

• Chan, Y. et al. 2023. (+)-catechin attenuates multiple atherosclerosis-associated processes in vitro, modulates disease-associated risk factors in C57BL/6J mice and reduces atherogenesis in LDL receptor deficient mice by inhibiting inflammation and increasing markers of plaque stability. Molecular Nutrition & Food Research 67 (14) 2200716. (10.1002/mnfr.202200716)
• Mazzarino, M. et al. 2023. Therapeutic targeting of chronic kidney disease-associated DAMPs differentially contributing to vascular pathology. Frontiers in Immunology 14 1240679. (10.3389/fimmu.2023.1240679)
• Schroeder, B. E. , Robertson, N. P. and Hughes, T. A. T. 2023. Cerebral amyloid angiopathy: an update. Journal of Neurology 270 , pp.2809-2811. (10.1007/s00415-023-11631-3)
• Webberley, T. S. et al. 2023. Assessment of Lab4P probiotic effects on cognition in 3xTg-AD Alzheimer’s disease model mice and the SH-SY5Y neuronal cell line. International Journal of Molecular Sciences 24 (5) 4683. (10.3390/ijms24054683)

2022

• Carpanini, S. M. et al. 2022. Terminal complement pathway activation drives synaptic Loss in Alzheimer’s disease models. Acta Neuropathologica Communications 10 99. (10.1186/s40478-022-01404-w)
• Seidel, F. et al., 2022. Therapeutic intervention with anti-complement component 5 antibody does not reduce nash but does attenuate atherosclerosis and mif concentrations in ldlr-/-.Leiden mice. International Journal of Molecular Sciences 23 (18) 10736. (10.3390/ijms231810736)
• Webberley, T. S. et al., 2022. The impact of probiotic supplementation on cognitive, pathological and metabolic markers in a transgenic mouse model of Alzheimer’s Disease. Frontiers in Neuroscience 16 843105. (10.3389/fnins.2022.843105)
• Westacott, L. J. et al. 2022. Complement C3 and C3aR mediate different aspects of emotional behaviours; relevance to risk for psychiatric disorder. Brain, Behavior, and Immunity 99 , pp.70-82. (10.1016/j.bbi.2021.09.005)

2021

• Al-Ahmadi, W. et al., 2021. Pro-atherogenic actions of signal transducer and activator of transcription 1 serine 727 phosphorylation in LDL receptor deficient mice via modulation of plaque inflammation. FASEB Journal 35 (10) e21892. (10.1096/fj.202100571RR)
• Baker, L. et al., 2021. A genome guided evaluation of the Lab4 probiotic consortium. Genomics 113 (6), pp.4028-4038. (10.1016/j.ygeno.2021.08.007)
• Moss, J. W. E. et al. 2021. Protective effects of a unique combination of nutritionally active ingredients on risk factors and gene expression associated with atherosclerosis in C57BL/6J mice fed a high fat diet. Food and Function 12 (8), pp.3657-3671. (10.1039/D0FO02867C)
• Mullish, B. H. et al., 2021. Probiotics reduce self-reported symptoms of upper respiratory tract infection in overweight and obese adults: should we be considering probiotics during viral pandemics?. Gut Microbes 13 (1), pp.1-9. (10.1080/19490976.2021.1900997)
• Webberley, T. S. et al., 2021. The impact of Lab4 probiotic supplementation in a 90-Day study in wistar rats. Frontiers in Nutrition 8 778289. (10.3389/fnut.2021.778289)
• Westacott, L. J. et al. 2021. Dissociable effects of complement C3 and C3aR on survival and morphology of adult born hippocampal neurons, pattern separation, and cognitive flexibility in male mice. Brain, Behavior, and Immunity 98 , pp.136-150. (10.1016/j.bbi.2021.08.215)

2020

• Bevan, R. J. et al. 2020. Retinal ganglion cell degeneration correlates with hippocampal spine loss in experimental Alzheimer's disease. Acta Neuropathologica Communications 8 (1) 216. (10.1186/s40478-020-01094-2)
• Michael, D. R. et al., 2020. A randomised controlled study shows supplementation of overweight and obese adults with lactobacilli and bifidobacteria reduces bodyweight and improves well-being. Scientific Reports 10 (1), pp.-. 4183. (10.1038/s41598-020-60991-7)

2019

• Michael, D. et al., 2019. In vitro neuroprotective activities of two distinct probiotic consortia. Beneficial Microbes 10 (4), pp.437-447. (10.3920/BM2018.0105)

2018

• Boshra, H. et al., 2018. Absence of CD59 in guinea pigs: Analysis of the Cavia porcellus genome suggests the evolution of a CD59 pseudogene. Journal of Immunology 200 (1), pp.327-335. (10.4049/jimmunol.1701238)

2017

• Bergfeld, A. et al., 2017. Direct binding of the pH-regulated protein 1 (Pra1) from Candida albicans inhibits cytokine secretion by mouse CD4+ T cells. Frontiers in Microbiology 8 (10.3389/fmicb.2017.00844)
• Granados-Durán, P. et al., 2017. Microbial neuraminidase induces a moderate and transient myelin vacuolation independent of complement system activation. Frontiers in Neurology 8 78. (10.3389/fneur.2017.00078)
• Michael, D. R. et al., 2017. The anti-cholesterolaemic effect of a consortium of probiotics: An acute study in C57BL/6J mice. Scientific Reports 7 2883. (10.1038/s41598-017-02889-5)

2016

• Bloom, A. C. et al., 2016. Deletion of the membrane complement inhibitor CD59a drives age and gender-dependent alterations to bone phenotype in mice. Bone 84 , pp.253-261. (10.1016/j.bone.2015.12.014)
• Granados-Duran, P. et al., 2016. Complement system activation contributes to the ependymal damage induced by microbial neuraminidase. Journal of Neuroinflammation 13 (115)(10.1186/s12974-016-0576-9)
• Towner, L. D. et al., 2016. Complement membrane attack and tumorigenesis: a systems biology approach. Journal of Biological Chemistry 291 (29), pp.14927-14938. (10.1074/jbc.M115.708446)
• Triantafilou, M. et al. 2016. Complementing the inflammasome. Immunology 147 (2), pp.152-164. (10.1111/imm.12556)

2015

• Davies, T. S. et al., 2015. Interferon gamma signalling in atherosclerosis: pro-atherogenic actions and therapeutic approaches. Cardiology 131 , pp.292-292.
• McCully, M. L. et al. 2015. Skin metabolites define a new paradigm in the localization of skin tropic memory T cells. Journal of Immunology 195 (1), pp.96-104. (10.4049/jimmunol.1402961)
• Ramaglia, V. et al., 2015. Complement activation and expression during chronic relapsing experimental autoimmune encephalomyelitis in the Biozzi ABH mouse. Clinical & Experimental Immunology 180 (3), pp.432-441. (10.1111/cei.12595)

2014

• Davies, T. S. et al., 2014. Pro- therogenic actions of interferon-gamma on macrophages in atherosclerosis. Cardiology 128 (S1), pp.278-278. (10.1159/000365062)
• Steiner, T. et al., 2014. Protective role for properdin in progression of experimental murine atherosclerosis. PLoS ONE 9 (3) e92404. (10.1371/journal.pone.0092404)
• Towner, L. , Hughes, T. and Morgan, B. P. 2014. Exploring the effects of non-lethal complement membrane attack on CT26 Colon Carcinoma cells using network analysis of differentially expressed genes. Molecular Immunology 61 (2), pp.245-246.

2013

• Kandasamy, M. et al., 2013. Complement mediated signaling on pulmonary CD103+ dendritic cells is critical for their migratory function in response to influenza infection. PLoS Pathogens 9 (1) e1003115. (10.1371/journal.ppat.1003115)
• Killick, R. et al., 2013. Corrigendum to “Deletion of Crry, the murine ortholog of the sporadic Alzheimer's disease risk gene CR1, impacts tau phosphorylation and brain CFH” [Neurosci. Lett. 533 (2013) 96–99] [Corrigendum]. Neuroscience Letters 545 , pp.144-144. (10.1016/j.neulet.2013.05.004)
• Killick, R. et al., 2013. Deletion of Crry, the murine ortholog of the sporadic Alzheimer's disease risk gene CR1, impacts tau phosphorylation and brain CFH. Neuroscience Letters 533 , pp.96-99. (10.1016/j.neulet.2012.11.008)
• Laudisi, F. et al., 2013. Cutting edge: The NLRP3 inflammasome links complement-mediated inflammation and IL-1β release. The Journal of Immunology 191 (3), pp.1006-1010. (10.4049/jimmunol.1300489)
• Triantafilou, K. et al. 2013. The complement membrane attack complex triggers intracellular Ca2+ fluxes leading to NLRP3 inflammasome activation. Journal of Cell Science 126 (13), pp.2903-2913. (10.1242/jcs.124388)

2012

• Ramaglia, V. et al. 2012. C3-dependent mechanism of microglial priming relevant to multiple sclerosis. Proceedings of the National Academy of Sciences 109 (3), pp.965-970. (10.1073/pnas.1111924109)

2011

• Lewis, R. D. et al. 2011. CD55 deficiency protects against atherosclerosis in ApoE-deficient mice via C3a modulation of lipid metabolism. American Journal of Pathology 179 (4), pp.1601-1607. (10.1016/j.ajpath.2011.06.015)
• Lueck, K. et al., 2011. Sub-lytic C5b-9 induces functional changes in retinal pigment epithelial cells consistent with age-related macular degeneration. Eye 25 (8), pp.1074-1082. (10.1038/eye.2011.109)

2010

• Copland, D. A. et al., 2010. Systemic and local anti-C5 therapy reduces the disease severity in experimental autoimmune uveoretinitis. Clinical and Experimental Immunology 159 (3), pp.303-314. (10.1111/j.1365-2249.2009.04070.x)
• Gray, L. C. , Hughes, T. R. and Van Den Berg, C. W. 2010. Binding of human antigen R (HuR) to an AU-rich element (ARE) in the 3' untranslated region (3' UTR) reduces the expression of decay accelerating factor (DAF). Molecular Immunology 47 (16), pp.2545-2551. (10.1016/j.molimm.2010.07.002)
• Lewis, R. D. et al. 2010. The membrane attack complex of complement drives the progression of atherosclerosis in apolipoprotein E knockout mice. Molecular Immunology 47 (5), pp.1098-1105. (10.1016/j.molimm.2009.10.035)

2009

• Hughes, T. R. et al. 2009. Identification of the high affinity binding site in the Streptococcus intermedius toxin intermedilysin for its membrane receptor, the human complement regulator CD59. Molecular Immunology 46 (7), pp.1561-1567. (10.1016/j.molimm.2009.01.003)
• Ruseva, M. M. et al. 2009. Crry deficiency in complement sufficient mice: C3 consumption occurs without associated renal injury. Molecular Immunology 46 (5), pp.803-811. (10.1016/j.molimm.2008.09.003)

2008

• Donev, R. M. et al. 2008. Modulation of CD59 expression by restrictive silencer factor-derived peptides in cancer immunotherapy for neuroblastoma [RETRACTED]. Cancer Research 68 (14), pp.5979-5987. (10.1158/0008-5472.CAN-07-6828)

2007

• Sivasankar, B. et al., 2007. CD59a deficient mice display reduced B cell activity and antibody production in response to T-dependent antigens. Molecular Immunology 44 (11), pp.2978-2987. (10.1016/j.molimm.2006.12.025)

2006

• Donev, R. M. et al. 2006. p53 regulates cellular resistance to complement lysis through enhanced expression of CD59 [RETRACTED]. Cancer Research 66 (4), pp.2451-8. (10.1158/0008-5472.CAN-05-3191)
• Irvine, S. A. et al., 2006. Lipoprotein lipase is expressed by glomerular mesangial cells. The International Journal of Biochemistry & Cell Biology 38 (1), pp.12-16. (10.1016/j.biocel.2005.07.008)

2003

• Mead, J. R. et al., 2003. Interferon-γ stimulates the expression of the inducible cAMP early repressor in macrophages through the activation of casein kinase 2: A Potentially novel pathway for interferon-γ-mediated inhibition of gene transcription. Journal of Biological Chemistry , pp.17741-17751. (10.1074/jbc.M301602200)

2002

• Hughes, T. R. et al. 2002. A novel role of Sp1 and Sp3 in the interferon- -mediated suppression of macrophage lipoprotein lipase gene transcription. Journal of Biological Chemistry 277 (13), pp.11097-11106. (10.1074/jbc.M106774200)

2001

• Kockar, F. T. et al., 2001. Analysis of the Xenopus laevis CCAAT-enhancer binding protein α gene promoter demonstrates species-specific differences in the mechanisms for both auto-activation and regulation by Sp1. Nucleic Acids Research 29 (2), pp.362-372. (10.1093/nar/29.2.362)

2000

• Granger, R. L. , Hughes, T. R. and Ramji, D. P. 2000. Gene, stimulus and cell-type specific regulation of activator protein-1 in mesangial cells by lipopolysaccharide and cytokines. Biochimica et Biophysica Acta (BBA) - Gene Structure and Expression 1492 (1), pp.100-107. (10.1016/S0167-4781(00)00089-0)
• Granger, R. L. , Hughes, T. R. and Ramji, D. P. 2000. Stimulus- and cell-type-specific regulation of CCAAT-enhancer binding protein isoforms in glomerular mesangial cells by lipopolysaccharide and cytokines. Biochimica et Biophysica Acta - Molecular Basis of Disease 1501 (2-3), pp.171-179. (10.1016/S0925-4439(00)00016-8)